NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis $0.81 +0.01 (+1.66%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.01 (+1.86%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearside Biomedical Stock (NASDAQ:CLSD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clearside Biomedical alerts:Sign Up Key Stats Today's Range$0.79▼$0.8350-Day Range$0.74▼$0.9052-Week Range$0.70▼$1.65Volume88,403 shsAverage Volume359,669 shsMarket Capitalization$62.63 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingBuy Company Overview Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Read More Clearside Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreCLSD MarketRank™: Clearside Biomedical scored higher than 36% of companies evaluated by MarketBeat, and ranked 754th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 3 research reports in the past 90 days.Read more about Clearside Biomedical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Clearside Biomedical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.48% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 181.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.48% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 181.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentClearside Biomedical has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Clearside Biomedical this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Stock News HeadlinesShareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years agoJune 28, 2025 | finance.yahoo.comClearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit MeetingJune 17, 2025 | globenewswire.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 2 at 2:00 AM | Crypto Swap Profits (Ad)Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology ForumMay 21, 2025 | globenewswire.comClearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.com7CLSD : A Peek at Clearside Biomedical's Future EarningsMay 14, 2025 | benzinga.comClearside Biomedical Q1 2025 Earnings PreviewMay 14, 2025 | msn.comClearside Biomedical at The Citizens Conference: Strategic Trial InsightsMay 9, 2025 | investing.comSee More Headlines CLSD Stock Analysis - Frequently Asked Questions How have CLSD shares performed this year? Clearside Biomedical's stock was trading at $0.95 at the start of the year. Since then, CLSD stock has decreased by 15.2% and is now trading at $0.8060. View the best growth stocks for 2025 here. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm earned $2.33 million during the quarter, compared to the consensus estimate of $0.20 million. When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ). Company Calendar Last Earnings5/14/2025Today7/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLSD CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+477.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.35 million Net Margins-818.57% Pretax Margin-799.60% Return on EquityN/A Return on Assets-114.23% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$1.66 million Price / Sales38.48 Cash FlowN/A Price / Cash FlowN/A Book Value($0.51) per share Price / Book-1.61Miscellaneous Outstanding Shares77,710,000Free Float72,891,000Market Cap$63.88 million OptionableOptionable Beta2.05 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CLSD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.